These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26759322)

  • 1. Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns.
    Miyamura K
    Int J Hematol; 2016 Feb; 103(2):155-64. PubMed ID: 26759322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study.
    Muroi K; Miyamura K; Okada M; Yamashita T; Murata M; Ishikawa T; Uike N; Hidaka M; Kobayashi R; Imamura M; Tanaka J; Ohashi K; Taniguchi S; Ikeda T; Eto T; Mori M; Yamaoka M; Ozawa K
    Int J Hematol; 2016 Feb; 103(2):243-50. PubMed ID: 26608364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
    PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
    Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
    Bonig H; Kuçi Z; Kuçi S; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; Teichert von Luettichau I; Herter-Sprie G; Ashab Uddin M; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Paneesha S; Novitzky-Basso I; Gefen A; Nevo N; Beutel G; Schlegel PG; Klingebiel T; Bader P
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mesenchymal stem cells for treatment of graft-versus-host disease].
    Najima Y
    Rinsho Ketsueki; 2017; 58(12):2440-2449. PubMed ID: 29332881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
    Zhao L; Chen S; Yang P; Cao H; Li L
    Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature.
    Munneke JM; Spruit MJ; Cornelissen AS; van Hoeven V; Voermans C; Hazenberg MD
    Transplantation; 2016 Nov; 100(11):2309-2314. PubMed ID: 26714122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
    Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bone marrow mesenchymal stem cells on hematopoietic recovery and acute graft-versus-host disease in murine allogeneic umbilical cord blood transplantation model.
    Li ZY; Wang CQ; Lu G; Pan XY; Xu KL
    Cell Biochem Biophys; 2014 Sep; 70(1):115-22. PubMed ID: 24696072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.
    Morata-Tarifa C; Macías-Sánchez MDM; Gutiérrez-Pizarraya A; Sanchez-Pernaute R
    Stem Cell Res Ther; 2020 Feb; 11(1):64. PubMed ID: 32070420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
    Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
    Front Immunol; 2022; 13():959658. PubMed ID: 36189324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remestemcel-L for the treatment of graft versus host disease.
    Locatelli F; Algeri M; Trevisan V; Bertaina A
    Expert Rev Clin Immunol; 2017 Jan; 13(1):43-56. PubMed ID: 27399600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis.
    Hashmi S; Ahmed M; Murad MH; Litzow MR; Adams RH; Ball LM; Prasad VK; Kebriaei P; Ringden O
    Lancet Haematol; 2016 Jan; 3(1):e45-52. PubMed ID: 26765648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation.
    Dotoli GM; De Santis GC; Orellana MD; de Lima Prata K; Caruso SR; Fernandes TR; Rensi Colturato VA; Kondo AT; Hamerschlak N; Simões BP; Covas DT
    Bone Marrow Transplant; 2017 Jun; 52(6):859-862. PubMed ID: 28287644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.
    von Dalowski F; Kramer M; Wermke M; Wehner R; Röllig C; Alakel N; Stölzel F; Parmentier S; Sockel K; Krech M; Schmitz M; Platzbecker U; Schetelig J; Bornhäuser M; von Bonin M
    Stem Cells; 2016 Feb; 34(2):357-66. PubMed ID: 26418955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
    Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease.
    Soder RP; Dawn B; Weiss ML; Dunavin N; Weir S; Mitchell J; Li M; Shune L; Singh AK; Ganguly S; Morrison M; Abdelhakim H; Godwin AK; Abhyankar S; McGuirk J
    Stem Cell Rev Rep; 2020 Oct; 16(5):979-991. PubMed ID: 32740891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease.
    Kurtzberg J; Abdel-Azim H; Carpenter P; Chaudhury S; Horn B; Mahadeo K; Nemecek E; Neudorf S; Prasad V; Prockop S; Quigg T; Satwani P; Cheng A; Burke E; Hayes J; Skerrett D;
    Biol Blood Marrow Transplant; 2020 May; 26(5):845-854. PubMed ID: 32018062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.